0

Tetanus Toxoid Vaccine Market by Age Group and Geography - Forecast and Analysis 2022-2026

  • Published: May 2022
  • Pages: 120
  • SKU: IRTNTR73401
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

According to Technavio's analyst, the tetanus toxoid vaccine market size is expected to be valued at USD 1.17 billion by 2026 with a progressing CAGR of 4.3%.

This tetanus toxoid vaccine market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The tetanus toxoid vaccine market report also offers information on several market vendors, including Actiza Pharmaceutical Pvt. Ltd., AJ Vaccines AS, Amson Vaccines and Pharma Pvt Ltd., Avalon Pharma Pvt. Ltd., Bharat Biotech Ltd., CSL Ltd., Dano Vaccines and Biologicals Pvt. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Grifols SA, Incepta Vaccine Ltd., Meiji Holdings Co. Ltd., Merck and Co. Inc., Microgen, Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd., and Zoetis Inc. among others.

The tetanus toxoid vaccine market has been broadly categorized into the following demographic segmentations: 

  • Age group - Neonatals and adults
  • Geography - North America, Europe, Asia, and Rest of World (ROW)

What will the Tetanus Toxoid Vaccine Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Tetanus Toxoid Vaccine Market Size for the Forecast Period and Other Important Statistics

 

Tetanus Toxoid Vaccine Market: Key Drivers, Trends, and Challenges

The licensing agreements is notably driving the tetanus toxoid vaccine market growth, although factors such as the high cost of healthcare may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the tetanus toxoid vaccine industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Tetanus Toxoid Vaccine Market Driver

  • The licensing agreements is one of the key drivers fueling the tetanus toxoid vaccine market growth.
  • The licensing agreements in the global tetanus toxoid market enable the company to expand the reach of the product to multiple nations with relatively less involvement and risk.
  • For instance, Genticel SA, a French biotechnology company that develops therapeutic vaccines, licensed its Vaxiclase technology to Serum Institute of India Ltd. (SIIL).
  • One of the licensing and marketing agreement took place in the global tetanus toxoid vaccine market between Takeda Pharmaceutical Company (Takeda) and Biological E. Ltd. (BE), which expedited the development and delivery of low-cost combination vaccines, including DTaP vaccines.
  • Significantly, BE has the right to use Takeda's pertussis vaccine technology for any pertussis-containing combination vaccine. Thus, such licensing agreements benefit market vendors and will help drive the growth of the global tetanus toxoid vaccine market during the forecast period. 

Key Tetanus Toxoid Vaccine Market Trend

  • New product launches is one of the key tetanus toxoid vaccine market trends that is positively impacting the market growth.
  • Vendors in the market adopt strategies such as new product launches to tackle the competition in the market.
  • Vendors invest in developing innovative and advanced tetanus toxoid vaccines to increase their foothold in the market. 
  • In November 2021, Stablepharma Ltd., in partnership with European vaccine manufacturer BB-NCIPD Ltd. (Bul Bio), developed a thermally stable version of the Td vaccine using the patented StablevaX formulation. 
  • In September 2020, Sanofi Pasteur India announced the launch of Tetraxim (DTaP-IPV), a vaccine developed for children to prevent diseases such as diphtheria, pertussis, tetanus, and polio. Such new product launches will propel the tetanus toxoid vaccine market growth during the forecast period.

Key Tetanus Toxoid Vaccine Market Challenge

  • The high cost of healthcare is one of the challenges impeding the tetanus toxoid vaccine market growth.
  • The US has the most expensive healthcare system compared to other nations.
  • According to the Organization for Economic Co-operation and Development (OECD) in 2020, the per capita expenditure in the UK increased by 12.8 in 2020 over 2019.
  • The high cost of healthcare in developed countries prevents patients from availing of tetanus toxoid vaccines.
  • The absence of proper healthcare infrastructure and less government aid received in the form of medical expense reimbursement further poses a challenge for the patients in developing countries. This, in turn, will negatively impact the tetanus toxoid vaccine market growth during the forecast period.

This tetanus toxoid vaccine market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Who are the Major Tetanus Toxoid Vaccine Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Actiza Pharmaceutical Pvt. Ltd.
  • AJ Vaccines AS
  • Amson Vaccines and Pharma Pvt Ltd.
  • Avalon Pharma Pvt. Ltd.
  • Bharat Biotech Ltd.
  • CSL Ltd.
  • Dano Vaccines and Biologicals Pvt. Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Grifols SA
  • Incepta Vaccine Ltd.
  • Meiji Holdings Co. Ltd.
  • Merck and Co. Inc.
  • Microgen
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co. Ltd.
  • Zoetis Inc.

 

This statistical study of the tetanus toxoid vaccine market encompasses successful business strategies deployed by the key vendors. The tetanus toxoid vaccine market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

  • Avalonpharma.com - The company offers Tetanus toxoid vaccine adsorbed 5lf injection, which helps to develop immunity by initiating a mild infection.
  • Bharatbiotech.com - The company offers tetanus toxoid vaccines such as Comvac 3 and Comvac 4.
  • Emergentbiosolutions.com - The company offers tetanus toxoid vaccine named BioThrax (Anthrax Vaccine Adsorbed).

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The tetanus toxoid vaccine market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Which are the Key Regions for Tetanus Toxoid Vaccine Market?

For more insights on the market share of various regions Request for a FREE sample now!

39% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the tetanus toxoid vaccine market in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).

 The higher coverage provided to end-users will facilitate the tetanus toxoid vaccine market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the COVID-19 pandemic had a negative impact on the regional tetanus toxoid vaccine market. However, in 2021, due to the availability of COVID-19 vaccines, the number of COVID-19 cases in the region declined. Thus, due to the ease of COVID-related restrictions and access to hospitals and clinics restored, the demand for tetanus toxoid vaccines rebounded. Thus, due to these factors, the regional tetanus toxoid vaccine market will continue to grow during the forecast period.

What are the Revenue-generating Age Group Segments in the Tetanus Toxoid Vaccine Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The tetanus toxoid vaccine market share growth by the neonatals segment will be significant during the forecast period. Neonatal tetanus is a significant cause of neonatal mortality as it has a case-fatality rate of 80%-100%. The disease is more prevalent in rural areas, especially in low-income countries, where deliveries occur at home in an unclean environment and without adequate sterile procedures. However, neonatal tetanus can be prevented through immunization with tetanus toxoid vaccines. Thus, these factors will continue to drive the growth of the global tetanus toxoid vaccine market during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the tetanus toxoid vaccine market size and actionable market insights on post COVID-19 impact on each segment.

Parent Market Analysis

Technavio categorizes the global tetanus toxoid vaccine market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the tetanus toxoid vaccine market during the forecast period.

Tetanus Toxoid Vaccine Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the tetanus toxoid vaccine market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

 

Tetanus Toxoid Vaccine Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 4.3%

Market growth 2022-2026

$ 1.17 billion

Market structure

Fragmented

YoY growth (%)

3.7

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 39%

Key consumer countries

US, Canada, Germany, UK, and France

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Actiza Pharmaceutical Pvt. Ltd., AJ Vaccines AS, Amson Vaccines and Pharma Pvt Ltd., Avalon Pharma Pvt. Ltd., Bharat Biotech Ltd., CSL Ltd., Dano Vaccines and Biologicals Pvt. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Grifols SA, Incepta Vaccine Ltd., Meiji Holdings Co. Ltd., Merck and Co. Inc., Microgen, Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd., and Zoetis Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Tetanus Toxoid Vaccine Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive tetanus toxoid vaccine market growth during the next five years
  • Precise estimation of the tetanus toxoid vaccine market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the tetanus toxoid vaccine industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of tetanus toxoid vaccine market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Age Group
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Age Group

    • 5.1 Market segments
      • Exhibit 24: Chart on Age Group - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Age Group - Market share 2021-2026 (%)
    • 5.2 Comparison by Age Group
      • Exhibit
        26: Chart on Comparison by Age Group
      • Exhibit 27: Data Table on Comparison by Age Group
    • 5.3 Neonatals - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Neonatals - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Neonatals - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Neonatals - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Neonatals - Year-over-year growth 2021-2026 (%)
    • 5.4 Adults - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Adults - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Adults - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Adults - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Adults - Year-over-year growth 2021-2026 (%)
    • 5.5 Market opportunity by Age Group
      • Exhibit 36: Market opportunity by Age Group ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 40: Chart on Geographic comparison
      • Exhibit 41: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Germany - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.9 UK - Market size and forecast 2021-2026
      • Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.10 France - Market size and forecast 2021-2026
      • Exhibit 70: Chart on France - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on France - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on France - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on France - Year-over-year growth 2021-2026 (%)
    • 7.11 Canada - Market size and forecast 2021-2026
      • Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 78: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 81: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 82: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 83: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 84: Matrix on vendor position and classification
            • 10.3 Avalon Pharma Pvt. Ltd.
              • Exhibit 85: Avalon Pharma Pvt. Ltd. - Overview
              • Exhibit 86: Avalon Pharma Pvt. Ltd. - Product / Service
              • Exhibit 87: Avalon Pharma Pvt. Ltd. - Key offerings
            • 10.4 Bharat Biotech Ltd.
              • Exhibit 88: Bharat Biotech Ltd. - Overview
              • Exhibit 89: Bharat Biotech Ltd. - Product / Service
              • Exhibit 90: Bharat Biotech Ltd. - Key news
              • Exhibit 91: Bharat Biotech Ltd. - Key offerings
            • 10.5 Emergent BioSolutions Inc.
              • Exhibit 92: Emergent BioSolutions Inc. - Overview
              • Exhibit 93: Emergent BioSolutions Inc. - Product / Service
              • Exhibit 94: Emergent BioSolutions Inc. - Key news
              • Exhibit 95: Emergent BioSolutions Inc. - Key offerings
            • 10.6 GlaxoSmithKline Plc
              • Exhibit 96: GlaxoSmithKline Plc - Overview
              • Exhibit 97: GlaxoSmithKline Plc - Business segments
              • Exhibit 98: GlaxoSmithKline Plc - Key news
              • Exhibit 99: GlaxoSmithKline Plc - Key offerings
              • Exhibit 100: GlaxoSmithKline Plc - Segment focus
            • 10.7 Merck and Co. Inc.
              • Exhibit 101: Merck and Co. Inc. - Overview
              • Exhibit 102: Merck and Co. Inc. - Business segments
              • Exhibit 103: Merck and Co. Inc. - Key news
              • Exhibit 104: Merck and Co. Inc. - Key offerings
              • Exhibit 105: Merck and Co. Inc. - Segment focus
            • 10.8 Panacea Biotec Ltd.
              • Exhibit 106: Panacea Biotec Ltd. - Overview
              • Exhibit 107: Panacea Biotec Ltd. - Product / Service
              • Exhibit 108: Panacea Biotec Ltd. - Key offerings
            • 10.9 Pfizer Inc.
              • Exhibit 109: Pfizer Inc. - Overview
              • Exhibit 110: Pfizer Inc. - Product / Service
              • Exhibit 111: Pfizer Inc. - Key news
              • Exhibit 112: Pfizer Inc. - Key offerings
            • 10.10 Sanofi
              • Exhibit 113: Sanofi - Overview
              • Exhibit 114: Sanofi - Business segments
              • Exhibit 115: Sanofi - Key news
              • Exhibit 116: Sanofi - Key offerings
              • Exhibit 117: Sanofi - Segment focus
            • 10.11 Serum Institute of India Pvt. Ltd.
              • Exhibit 118: Serum Institute of India Pvt. Ltd. - Overview
              • Exhibit 119: Serum Institute of India Pvt. Ltd. - Product / Service
              • Exhibit 120: Serum Institute of India Pvt. Ltd. - Key offerings
            • 10.12 Shenzhen Kangtai Biological Products Co. Ltd.
              • Exhibit 121: Shenzhen Kangtai Biological Products Co. Ltd. - Overview
              • Exhibit 122: Shenzhen Kangtai Biological Products Co. Ltd. - Product / Service
              • Exhibit 123: Shenzhen Kangtai Biological Products Co. Ltd. - Key offerings

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 124: Inclusions checklist
                • Exhibit 125: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 126: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 127: Research methodology
                • Exhibit 128: Validation techniques employed for market sizing
                • Exhibit 129: Information sources
              • 11.5 List of abbreviations
                • Exhibit 130: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your FREE sample now!
              The tetanus toxoid vaccine market growth will increase by $1178.92 million during 2022-2026.
              The tetanus toxoid vaccine market is expected to grow at a CAGR of 4.3% during 2022-2026.
              Technavio has segmented the tetanus toxoid vaccine market by geographic (North America, Europe, Asia, and Rest of World (ROW)).
              Actiza Pharmaceutical Pvt. Ltd., AJ Vaccines AS, Amson Vaccines and Pharma Pvt Ltd., Avalon Pharma Pvt. Ltd., Bharat Biotech Ltd., CSL Ltd., Dano Vaccines and Biologicals Pvt. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Grifols SA, Incepta Vaccine Ltd., Meiji Holdings Co. Ltd., Merck and Co. Inc., Microgen, Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Zoetis Inc. are a few of the key vendors in the tetanus toxoid vaccine market.
              North America will register the highest growth rate of 39.45% among the other regions. Therefore, the tetanus toxoid vaccine market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the tetanus toxoid vaccine market growth are:
              • Licensing agreements

                The global tetanus toxoid vaccine market vendors are continuously entering into licensing agreements to offer their vaccines across various geographical regions. Vendors opt for licensing agreements and strategic alliances to improve their market reach and customer base. These strategic alliances among vendors are helping them enhance their operations and increase their geographical presence. 

                The licensing agreements in the global tetanus toxoid market enable the company to expand the reach of the product to multiple nations with relatively less involvement and risk. For instance, Genticel SA, a French biotechnology company that develops therapeutic vaccines, licensed its Vaxiclase technology to Serum Institute of India Ltd. (SIIL). SIIL uses the technology as a component in acellular multivalent combination vaccines, including pertussis vaccines. The license offered by Genticel to SIIL covers all countries of the world except key pharmaceutical markets such as the US, Canada, New Zealand, Australia, Japan, Israel, and Turkey. 

                Another licensing and marketing agreement took place in the global tetanus toxoid vaccine market between Takeda Pharmaceutical Company (Takeda) and Biological E. Ltd. (BE), which expedited the development and delivery of low-cost combination vaccines, including DTaP vaccines. BE commercializes the vaccines in low and middle-income countries such as India and China, with unmet public health needs. Takeda has marketed pertussis vaccines for more than 20 years in the Japanese market. As a part of these agreements, BE uses production technology transferred from Takeda and conducts funding development activities for the combination vaccines. BE has the right to use Takeda's pertussis vaccine technology for any pertussis-containing combination vaccine. Thus, such licensing agreements benefit market vendors and will help drive the growth of the global tetanus toxoid vaccine market during the forecast period.


              • New product launches

                The tetanus toxoid vaccine market vendors should focus on grabbing business opportunities from the segment as it accounted for the largest market share in the base year.
              Safe and Secure SSL Encrypted
              Technavio

              Single User:

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Want to customize this report?

              This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

              We offer $1000 worth of FREE customization at the time of purchase
              Technavio
              Enquire Before Buying
              1. Home
              2. Health Care
              3. Published Report
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>